Primary care providers human papillomavirus vaccine recommendations for the medically underserved: A pilot study in U.S. federally qualified health centers

Vaccine

Volumn 32, Issue 42, 2014, Pages 5432-5435

  Roland, Katherine B ^a   Benard, Vicki B ^a   Greek, April ^b   Hawkins, Nikki A ^a   Saraiya, Mona ^a  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

Author keywords

Cervical cancer screening; Federally Qualified Health Center (FQHC); HPV vaccine; Low income; Underserved

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; COLPOSCOPY; FEMALE; HEALTH CENTER; HUMAN; MEDICALLY UNDERSERVED; PAPANICOLAOU TEST; PATIENT REFERRAL; PILOT STUDY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SEXUALITY; UNITED STATES; UTERINE CERVIX CANCER; VACCINATION; ATTITUDE TO HEALTH; CLINICAL PRACTICE; CROSS-SECTIONAL STUDY; EARLY DIAGNOSIS; GENERAL PRACTITIONER; HEALTH CARE PLANNING; MALE; PAPILLOMAVIRUS INFECTIONS; PRACTICE GUIDELINE; PRIMARY HEALTH CARE; QUESTIONNAIRE; STATISTICS AND NUMERICAL DATA; UTERINE CERVICAL NEOPLASMS;

CROSS-SECTIONAL STUDIES; EARLY DETECTION OF CANCER; FEMALE; GUIDELINE ADHERENCE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; ILLINOIS; MALE; MEDICALLY UNDERSERVED AREA; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS, PRIMARY CARE; PILOT PROJECTS; PRACTICE GUIDELINES AS TOPIC; PRIMARY HEALTH CARE; QUESTIONNAIRES; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 84922400374     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.07.098     Document Type: Article

References (27)

1. Human papillomavirus-associated cancers - United States, 2004-2008. MMWR Morb Mortal Wkly Rep 2012, 61:258-261.
2. Paavonen J., Naud P., Salmeron J., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374(9686):301-314.
3. National and state vaccination coverage among adolescents aged 13-17 years - United States, 2011. MMWR Morb Mortal Wkly Rep 2012, 61(34):671-677.
4. Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2. MMWR Morb Mortal Wkly Rep 2013, 62(29):591-595.
5. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010, 59(20):626-629.
6. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010, 59(20):630-632.
7. ACOG Committee Opinion No. 344: Human papillomavirus vaccination. Obstet Gynecol 2006, 108(3 Pt 1):699-705.
8. Jemal A., Simard E.P., Dorell C., et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 2013, 105(3):175-201.
9. Benard V.B., Johnson C.J., Thompson T.D., et al. Examining the association between socioeconomic status and potential human papillomavirus-associated cancers. Cancer 2008, 113(Suppl. 10):2910-2918.
10. Fedewa S.A., Cokkinides V., Virgo K.S., Bandi P., Saslow D., Ward E.M. Association of insurance status and age with cervical cancer stage at diagnosis: National Cancer Database, 2000-2007. Am J Public Health 2012, 102(9):1782-1790.
11. Guerry S.L., De Rosa C.J., Markowitz L.E., et al. Human papillomavirus vaccine initiation among adolescent girls in high-risk communities. Vaccine 2011, 29(12):2235-2241.
12. Holman D.M., Benard V., Roland K.B., Watson M., Liddon N., Stokley S. Barriers to human papillomavirus vaccination among US adolescents: a systematic review of the literature. JAMA Pediatr 2014, 168(1):76-82.
13. Saslow D., Castle P.E., Cox J.T., et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 2007, 57(1):7-28.
14. Ricciotti H.A., Girouard S., Pokorney G., Dodge L.E., Hacker M.R. Lessons learned from a Boston community health center promoting the human papilloma virus vaccine in a minority adult population. J Prim Care Community Health 2010, 1(1):50-54.
15. Benard V.B., Saraiya M., Greek A., et al. Overview of the CDC Cervical Cancer (Cx3) Study: an educational intervention of HPV testing for cervical cancer screening. J Womens Health (Larchmt) 2014, 23(3):197-203.
16. Benard V.B., Saraiya M.S., Soman A., Roland K.B., Yabroff K.R., Miller J. Cancer screening practices among physicians in the national breast and cervical cancer early detection program. J Womens Health (Larchmt) 2011, 20(10):1479-1484.
17. Roland K.B., Soman A., Benard V.B., Saraiya M. Human papillomavirus and Papanicolaou tests screening interval recommendations in the United States. Am J Obstet Gynecol 2011, 205(5):447-448.
18. Kepka D., Berkowitz Z., Yabroff K.R., Roland K., Saraiya M. Human papillomavirus vaccine practices in the USA: do primary care providers use sexual history and cervical cancer screening results to make HPV vaccine recommendations?. Sex Transm Infect 2012, 88(6):433-435.
19. Roland K.B., Benard V.B., Greek A., Hawkins N.A., Manninen D., Saraiya M. Primary care provider practices and beliefs related to cervical cancer screening with the HPV test in Federally Qualified Health Centers. Prev Med 2013, 57(5):419-425.
20. Young J.L., Bernheim R.G., Korte J.E., Stoler M.H., Guterbock T.M., Rice L.W. Human papillomavirus vaccination recommendation may be linked to reimbursement: a survey of Virginia family practitioners and gynecologists. J Pediatr Adolesc Gynecol 2011, 24(6):380-385.
21. Duval B., Gilca V., McNeil S., et al. Vaccination against human papillomavirus: a baseline survey of Canadian clinicians' knowledge, attitudes and beliefs. Vaccine 2007, 25(45):7841-7847.
22. Allen C.L., Harris J.R., Hannon P.A., et al. Opportunities for improving cancer prevention at federally qualified health centers. J Cancer Educ 2014, 29(1):30-37.
23. Martinez-Gutierrez J., Jhingan E., Angulo A., Jimenez R., Thompson B., Coronado G.D. Cancer screening at a federally qualified health center: a qualitative study on organizational challenges in the era of the patient-centered medical home. J Immigr Minor Health 2013, 15(5):993-1000.
24. Coronado G.D., Petrik A., Spofford M., et al. Perceptions of under and overutilization of cervical cancer screening services at Latino-serving community health centers. J Community Health 2013, 38(5):915-918.
25. Wong C., Berkowitz Z., Saraiya M., Wideroff L., Benard V.B. US physicians' intentions regarding impact of human papillomavirus vaccine on cervical cancer screening. Sex Health 2010, 7(3):338-345.
26. Pathman D.E., Konrad T.R., Freed G.L., Freeman V.A., Koch G.G. The awareness-to-adherence model of the steps to clinical guideline compliance. The case of pediatric vaccine recommendations. Med Care 1996, 34(9):873-889.
27. Vadaparampil S.T., Malo T.L., Kahn J.A., et al. Physicians' human papillomavirus vaccine recommendations, 2009 and 2011. Am J Prev Med 2014, 46(1):80-84.